IMMUNOCORE HOLDINGS PLC

(IMCR)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Communiqués de presse de la société IMMUNOCORE HOLDINGS PLC
05/11Immunocore Reports First Quarter 2022 Financial Results and Provides Business Update
GL
04/18IMMUNOCORE : Corporate Presentation - April 2022
PU
04/07Immunocore to present at the 21st Annual Needham Healthcare Conference
AQ
04/04IMMUNOCORE : European Commission Approves KIMMTRAK® (tebentafusp) for the treatment of unr..
PU
04/04European Commission Approves KIMMTRAK® (tebentafusp) for the treatment of unresectable ..
GL
04/04European Commission Approves KIMMTRAK® (tebentafusp) for the treatment of unresectable ..
GL
03/09Immunocore to present at Oppenheimer's 32nd Annual Healthcare Conference
AQ
03/03IMMUNOCORE : Reports Full Year 2021 Financial Results and Provides Business Update - Form ..
PU
03/03Immunocore Reports Full Year 2021 Financial Results and Provides Business Update
GL
02/25Immunocore receives positive CHMP opinion for KIMMTRAK® (tebentafusp) for the treatment..
AQ
02/18IMMUNOCORE : Corporate Presentation - February 2022
PU
02/15ArriVent Biopharma Appoints Bahija Jallal to its Board of Directors
AQ
02/11Immunocore to present at the SVB Leerink Global Healthcare Conference
GL
02/11Immunocore to present at the SVB Leerink Global Healthcare Conference
GL
01/26IMMUNOCORE : announces FDA approval of KIMMTRAK® (tebentafusp-tebn) for the treatment of u..
PU
01/26Immunocore announces FDA approval of KIMMTRAK® (tebentafusp-tebn) for the treatment of ..
GL
01/10IMMUNOCORE : Corporate Presentation - January 2022
PU
01/06Immunocore to present at the 40th Annual J.P. Morgan Healthcare Conference
GL
2021IMMUNOCORE : announces initial Phase 1 data of ImmTAC® candidate IMC-C103C targeting MAGE-..
PU
2021IMMUNOCORE : Initial Phase 1 Data from MAGE-A4 Program
PU
2021IMMUNOCORE : Corporate Presentation - 2021
PU
2021Immunocore announces initial Phase 1 data of ImmTAC® candidate IMC-C103C targeting MAGE..
GL
2021Immunocore to present at the Jefferies London Healthcare Conference
GL
2021INDEX TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS - Form 6-K
PU
2021Corporate Presentation - November 2021
PU
2021Immunocore Reports Third Quarter 2021 Financial Results and Provides Business Update
GL
2021Immunocore presents new data on tebentafusp in metastatic cutaneous melanoma (mCM) and ..
AQ
2021IMMUNOCORE : and Medison Pharma Partner for Future Commercialization of Tebentafusp in Can..
GL
2021Immunocore and Medison Pharma Partner for Future Commercialization of Tebentafusp in Ca..
GL
2021IMMUNOCORE : announces publication of phase 3 data comparing tebentafusp with investigator..
AQ
2021IMMUNOCORE : Dr. Carolin Barth Joins MiroBio as CEO to Lead Precision Immunology Company F..
AQ
2021Immunocore presents data at the European Society for Medical Oncology (ESMO) Congress 2..
GL
2021IMMUNOCORE : Announces Upcoming Presentations at the European Society for Medical Oncology..
AQ
2021Immunocore to present at upcoming investor conferences
GL
2021Immunocore Announces UK's Medicines and Healthcare Products Regulatory Agency (MHRA) Ac..
GL
2021IMMUNOCORE : EMA Committee for Medicinal Products for Human Use accepted tebentafusp Marke..
PU
2021Immunocore Announces that U.S. Food and Drug Administration and European Medicines Agen..
GL
2021IMMUNOCORE : INDEX TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (Form ..
PU
2021Immunocore Reports Second Quarter 2021 Financial Results and Provides Business Update
GL
2021Immunocore presents clinical data further characterizing the overall survival benefit o..
GL
2021Immunocore to present at upcoming investor conferences
GL
2021Immunocore announces dosing of first patient with ImmTAV® bispecific molecule for chron..
GL
2021Immunocore Reports First Quarter 2021 Financial Results
GL
2021Immunocore Announces Upcoming Presentations at the 2021 American Society of Clinical On..
GL
2021IDEAYA BIOSCIENCES : Reports Darovasertib (IDE196) Monotherapy Overall Survival Data and O..
AQ
2021Immunocore presents phase 3 data comparing tebentafusp with investigator's choice in th..
GL
2021Immunocore Provides Business Update and Reports Full Year 2020 Financial Results
GL
2021Immunocore Announces Upcoming Presentations at the American Association for Cancer Rese..
GL
2021Immunocore's tebentafusp granted Breakthrough Therapy Designation for unresectable or m..
GL
Upcoming event on IMMUNOCORE HOLDINGS PLC